Related Experiment Video
Updated: May 2, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
5.3K
Antiangiogenic activity of hypoxylonol C
Miyuki Fukai1, Toshihiro Suzuki, Ikuko Nagasawa
1Department of Pharmacognosy and Phytochemistry, Meiji Pharmaceutical University , Noshio 2-522-1 Kiyose-shi, Tokyo 204-8588, Japan.
Journal of Natural Products
|March 6, 2014
Summary
Hypoxylonol C from H. truncatum mushroom inhibits human umbilical vein endothelial cell (HUVEC) migration and tube formation. This antiangiogenic activity may stem from cell cycle arrest and reduced adhesion molecule expression.
Area of Science:
- Natural Product Chemistry
- Molecular Biology
- Angiogenesis Research
Background:
- The mushroom Hypoxylon truncatum produces compounds with potential biological activities.
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Identifying novel antiangiogenic compounds is vital for cancer therapy development.
Purpose of the Study:
- To investigate the antiangiogenic effects of Hypoxylonol C (1).
- To elucidate the molecular mechanisms underlying the antiangiogenic activity of Hypoxylonol C (1) in HUVECs.
Main Methods:
- Isolation of Hypoxylonol C (1) from Hypoxylon truncatum.
- Assessment of HUVEC migration and tube formation assays.
- cDNA microarray analysis to identify gene expression changes.
- Real-time RT-PCR to validate gene expression alterations.
Main Results:
- Hypoxylonol C (1) significantly inhibited HUVEC migration and tube formation.
- cDNA microarray analysis revealed down-regulation of genes involved in cell cycle and adhesion.
- Real-time RT-PCR confirmed the down-regulation of these specific mRNA levels.
Conclusions:
- Hypoxylonol C (1) possesses antiangiogenic properties.
- Cell cycle arrest and suppression of adhesion molecule expression are potential mechanisms for its antiangiogenic activity.
- Hypoxylonol C (1) is a promising candidate for further investigation as an antiangiogenic agent.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
01:10Mechanism of Angiogenesis
6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K